topics / anti-estrogen
Tagged anti-estrogen.
- Strong human Anastrozole (Arimidex) Anastrozole is a non-steroidal aromatase inhibitor — a prescription breast-cancer drug, not a peptide — with strong trial evidence in postmenopausal women and a separate, unstudied off-label use by men to suppress estrogen. It is banned in sport at all times.
- Preliminary human Enclomiphene Enclomiphene is the anti-estrogenic isomer of clomiphene — a selective estrogen receptor modulator (SERM), not a peptide. Human trials consistently show it raises testosterone while preserving fertility, but it is NOT FDA-approved for any use, is available only via off-label compounding, and is banned in sport at all times.
- Strong human Exemestane (Aromasin) Exemestane is an oral, steroidal third-generation aromatase inhibitor — an FDA-approved breast-cancer drug, not a peptide. Bodybuilders use it off-label to suppress estrogen, an unapproved and unstudied practice that is banned in sport (WADA S4) and can be genuinely harmful when estrogen is crashed.
- Strong human Letrozole (Femara) Letrozole is an oral, nonsteroidal third-generation aromatase inhibitor — an FDA-approved breast-cancer and (off-label) fertility drug, not a peptide. Bodybuilders use it off-label to suppress estrogen, an unapproved and unstudied practice that is banned in sport (WADA S4) and can be genuinely harmful when estrogen is crashed.
- Strong human Raloxifene (Evista) Raloxifene is a selective estrogen receptor modulator (SERM) — an FDA-approved postmenopausal osteoporosis and breast-cancer-risk-reduction drug, not a peptide. Its defining serious risks are blood clots and fatal stroke; it is banned in sport at all times (WADA S4.2).
- Strong human Tamoxifen (Nolvadex) Tamoxifen is a selective estrogen receptor modulator (SERM) — an FDA-approved breast-cancer drug with one of the strongest evidence bases in oncology, not a peptide. Anabolic-steroid users take it off-label to blunt gynecomastia and attempt testosterone 'restart,' an unstudied practice that is banned in sport (WADA S4.2) and not without real risk.